



a


**Agonist-MC4R-G<sub>s</sub>αβγ-Nb35 complex formation**




**Protein-constructs**




b




c



d



e



**Fig. S2: Workflow and biochemistry data.**

(a) Workflow for the assembly of the MC4R–G<sub>s</sub>αβγ complexes stabilized by NDP-α-MSH or setmelanotide. MC4R–eGFP and G<sub>s</sub>αβγ (Gs) were expressed in *Sf9* and *Tni* cells, respectively. Gs was purified and added in excess to MC4R–eGFP expressing *Sf9* cells resuspended in a hypotonic buffer, containing apyrase, Nanobody 35 (Nb35) and 1 μM of agonists (NDP-α-MSH or setmelanotide). After overnight incubation membranes were resuspended in a buffer containing 1 % DDM and 0.1 % CHS. Followed by a FLAG M1 antibody purification. During the washing steps, DDM was exchanged against 0.01 % LMNG and 0.001 % CHS. After elution HRV-3C protease was added and the His<sub>6</sub> tag at Gβ and eGFP at MC4R was cleaved overnight. The agonist–MC4R–Gs–Nb35 complexes were separated from HRV-3C protease and remaining eGFP by size-exclusion chromatography using a Superdex 200 Increase 5/150 GL column for the complexes with

(b) NDP-α-MSH and

(c) setmelanotide. Subsequent SDS gel chromatography of

(d) NDP-α-MSH–MC4R–Gs–Nb35 and

(e) setmelanotide–MC4R–Gs–Nb35 were applied to confirm the stoichiometric ratio of MC4R and Gs. Gs-protein and Nb35 were used as controls in the last two lanes. For both complexes fractions B4 and B5 were concentrated and directly vitrified. Fig. S2a was created with *Biorender.com*.